image of silk fabric and dry skin
Drug ClassGeneric/Trade
Company Names
IndicationApproving
Regulatory Agency
Antiacne AgentClindamycin Foam 1%
Evoclin®
Connetics
Approved for topical application in the treatment of acne vulgarisUS FDA
Antibacterial
Agent
Cefdinir Oral Suspension
Omnicef®
Abbott Laboratories
A new 250mg/5ml dosing option approved for use in pediatric patients 6 months to 12 years of age. This more concentrated form allows parents to administer fewer teaspoons/ dose to their children.US FDA
Clindamycin
Evoclin® Foam 1%

Connetics
Approved for the treatment of mild-tomoderate acne vulgaris. Evoclin® was formerly referred to as Actiza™.US FDA
AntihistamineDesloratadine Syrup
CLARINEX®
Schering-Plough
Approved for the relief of symptoms associated with seasonal allergic rhinitis
in children >2 years of age, and perennial allergic rhinitis and chronic idiopathic urticaria, or hives of unknown cause in children as young as 6 months of age.
US FDA
Antipruritic AgentCetirizine HCl
Zyrtec®
Pfizer/UCB Pharma
A new chewable formulation approved for the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria in
children >2 years of age.
US FDA
Antipsoriatic AgentAlefacept
Amevive®
Biogen Idec
Approved for the treatment of adult patients with moderate-to-severe chronic plaque
psoriasis who are candidates for systemic therapy or phototherapy.
Israeli Ministry of
Health
Therapeutic Goods
Administration—
Australia
TPP Canada
Efalizumab
Raptiva®
Serono
Approved for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis.Swissmedic
CHMP Europe
Etanercept
Enbrel®
Amgen/Wyeth
Pharmaceuticals
Approved for the treatment of moderate-tosevere
plaque psoriasis who failed to respond
to, or have a contraindication to, or are
intolerant of other systemic therapy.
US FDA
CHMP Europe
Dermal FillerHyaluronic Acid Filler
Hyalite™
Mentor
Approved for soft tissue augmentation in the correction of wrinkles and folds and for lip enhancement.CHMP Europe
Hyaluronic Acid Filler
RESTYLANE®
Medicis
Approved for the correction of moderate-tosevere facial wrinkles and folds.US FDA
Hylan-B Gel
Hylaform
Inamed/Genzyme
Approved for injection into the mid-to-deep dermis for correction of moderate-to-severe facial wrinkles and folds.US FDA
Injectable Poly-L-Lactic Acid
Sculptra
Dermik Laboratories
Approved for the correction of lipoatrophy in people with HIV infection.US FDA
Enzyme Replacement
Therapy
Agalsidase Alfa
Replegal™
Transkaryotic Therapies
Approved for the treatment of Fabry disease under its Notice of Compliance with Conditions Policy, under which Transkaryotic Therapies can market this product while conducting post-marketing studiesTPP Canada
Immunomodulatory
Agent
Imiquimod Cream 5%
Aldara®
3M Pharmaceuticals
Approved for clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults.US FDA
TPP Canada

Imiquimod Cream 5%
Aldara®
3M Pharmaceuticals

Approved for the treatment of biopsyconfirmed, primary superficial basal cell carcinoma in adults with normal immune systems.US FDA
TPP Canada
Medical DeviceClinical Phototherapy
System

ClearTouch™ Light Unit
Assembly

Radiancy
Approved for the treatment of pustular inflammatory acne.US FDA
Ultrasonic Skin
Permeation Device

SonoPrep®
Sontra Medical
Approved for use with topical lidocaine.US FDA
Monoclonal AntibodySGN-30

Seattle Genetics

Granted Orphan Drug Designation for the treatment of T-cell lymphomas.US FDA
NeurotoxinBotulinum Toxin – Type A
BOTOX®
Allergan
Additional indication approved for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents.US FDA
Oncologic AgentMDX-010

Medarex

Granted Orphan Drug Designation for the treatment of high-risk Stage II, Stage III, and Stage IV melanoma.US FDA
Psoriatic Arthritis
Agent
Leflunomide
Arava®
Aventis
A new indication approved for the treatment of adult patients with active psoriatic arthritis.CHMP Europe
Etanercept
Enbrel®
Amgen/Wyeth
Pharmaceuticals
Approved for the treatment of psoriatic arthritis.
Etanercept
Enbrel®
Amgen/Wyeth
Pharmaceuticals
New dosing formula approved for the treatment of psoriatic arthritis and moderateto- severe plaque psoriasis – a prefilled syringe that will eliminate the need to mix the drug prior to injecting and will allow most patients receiving this drug to take only one injection/week instead of the two 25mg injections currently used weekly by patients.US FDA
Infliximab
REMICADE®
Schering-Plough/Centocor
Approved for use in combination with methotrexate for the treatment of active and progressive psoriatic arthritis in patients who have responded inadequately to diseasemodifying antirheumatic drugs.CHMP Europe